Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

SELL
$0.69 - $1.21 $269,064 - $471,838
-389,949 Reduced 47.62%
429,013 $413,000
Q1 2022

May 13, 2022

BUY
$1.02 - $3.8 $835,341 - $3.11 Million
818,962 New
818,962 $975,000
Q1 2021

May 13, 2021

SELL
$7.19 - $14.95 $623,373 - $1.3 Million
-86,700 Closed
0 $0
Q4 2020

Feb 10, 2021

BUY
$6.66 - $14.66 $577,422 - $1.27 Million
86,700 New
86,700 $941,000
Q3 2020

Nov 13, 2020

SELL
$8.69 - $14.47 $506,627 - $843,601
-58,300 Closed
0 $0
Q2 2020

Aug 13, 2020

BUY
$5.21 - $11.03 $303,743 - $643,049
58,300 New
58,300 $621,000
Q1 2020

May 14, 2020

SELL
$4.46 - $9.2 $575,719 - $1.19 Million
-129,085 Closed
0 $0
Q4 2019

Feb 13, 2020

SELL
$4.52 - $10.1 $711,967 - $1.59 Million
-157,515 Reduced 54.96%
129,085 $892,000
Q3 2019

Nov 13, 2019

SELL
$7.14 - $11.65 $77,112 - $125,820
-10,800 Reduced 3.63%
286,600 $2.98 Million
Q2 2019

Aug 12, 2019

BUY
$5.5 - $9.75 $422,950 - $749,775
76,900 Added 34.88%
297,400 $2.75 Million
Q1 2019

May 14, 2019

BUY
$5.51 - $9.59 $527,858 - $918,722
95,800 Added 76.82%
220,500 $2.02 Million
Q4 2018

Feb 13, 2019

BUY
$5.55 - $11.34 $692,085 - $1.41 Million
124,700 New
124,700 $695,000

About Syros Pharmaceuticals, Inc.


  • Ticker SYRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,236,200
  • Market Cap $4.86M
  • Description
  • Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for cancer and monogenic diseases, and building a pipeline of gene control medicines. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically def...
More about SYRS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.